Product Information
TRIBENZOR 40-10-25 MG TABLET is a brand product labeled by Cosette Pharmaceuticals, Inc., priced at $19.4141 per EA under NDC 00713087830. Its NADAC has been published 116 times since Jul 17, 2024.
FDA first approved this application on Jul 23, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
TRIBENZOR 40-10-25 MG TABLET
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazideStrength
10; 25; 40 mg/1; mg/1; mg/1
Manufacturer
Cosette Pharmaceuticals, Inc.NDC
00713087830
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
7/1/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
New Drug (NDA)
FDA Application
NDA200175FDA Approved
7/23/2010
TE Code
AB
On Market Since
9/1/2022
Pharmacological Classes
Price Statistics
The NADAC for TRIBENZOR 40-10-25 MG TABLET has been published 116 times since Jul 17, 2024, and over the history we have for it it has risen 32.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $19.4141 per EA |
|---|---|
| All-time high | $19.4141 (Sep 30, 2026) |
| All-time low | $14.6665 (Jul 17, 2024) |
| 52-week high | $19.4141 |
| 52-week low | $17.6653 |
| Median price | $16.1488 |
| Average price | $16.9473 |
| Largest weekly change | +10.0% (Sep 25, 2024) |
| Weeks tracked | 116 |
| Tracking since | Jul 17, 2024 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 95% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cosette Pharmaceuticals, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
olmesartan medoxomil / amlodipine besylate / hydrochlorothiazide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIBENZOR 40-10-25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRIBENZOR 40-10-25 MG TABLET, manufactured by Cosette Pharmaceuticals, Inc., is $19.4141 per EA (NDC 00713087830), effective Sep 30, 2026.
How has the price of TRIBENZOR 40-10-25 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRIBENZOR 40-10-25 MG TABLET has risen 32.4%. It has been tracked across 116 weekly CMS publications since Jul 17, 2024.
What are the highest and lowest recorded NADAC prices for TRIBENZOR 40-10-25 MG TABLET?
Since Jul 17, 2024, the NADAC for TRIBENZOR 40-10-25 MG TABLET has ranged from a low of $14.6665 (Jul 17, 2024) to a high of $19.4141 (Sep 30, 2026), with a median of $16.1488 per EA.
Are there cheaper alternatives to TRIBENZOR 40-10-25 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG, is $0.9895 per EA — about 95% below TRIBENZOR 40-10-25 MG TABLET.
Who manufactures TRIBENZOR 40-10-25 MG TABLET?
TRIBENZOR 40-10-25 MG TABLET (NDC 00713087830) is labeled by Cosette Pharmaceuticals, Inc., and CMS classifies it as a brand product.